Business Wire

Global Phased Array Ultrasonic Transducer Market to Surpass US$ 729.1 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global phased array ultrasonic transducer market is estimated to be valued at US$ 525.6 million in 2020 and is expected to exhibit ...
ascopubs.org

Transducer array layout optimization for the treatment of pancreatic cancer using Tumor Treating Fields (TTFields) in the phase 3 PANOVA-3 trial.

Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: A prospective, randomized, open label, single-center trial.
EurekAlert!

16-channel phased array electronics, along with a custom-built ultrasound transducer array and measurement results (IMAGE)

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
Pharmabiz

NovoCure begins patient enrollment in EF-33 phase 2 pilot trial of tumor treating fields delivered utilizing high-intensity transducer arrays

NovoCure announced that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent glioblastoma ...
Nasdaq

First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays

EF-33 will test the potential incremental survival benefit of Tumor Treating Fields delivered using high-intensity arrays in patients with recurrent glioblastoma ST. HELIER, Jersey--(BUSINESS WIRE)-- ...